Condition (MeSH)
Gingival Hyperplasia
ClinicalTrials.gov lists 18 trials for Gingival Hyperplasia or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
18 of the 18 trials are tagged with Gingival Hyperplasia itself; the rest are tagged with a narrower condition beneath it.
When did Gingival Hyperplasia trials start? (12)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 3
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 3 |
| 2024 | 2 |
| 2022 | 3 |
| 2021 | 1 |
| 2020 | 1 |
| 2019 | 2 |
| 2017 | 1 |
| 2016 | 1 |
| 2012 | 1 |
Showing 10 of 12 earlier years.
No forecast is made for this condition: it averages 1.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Gingival Hyperplasia trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 3 | 2 |
| Not applicable | 13 |
| Observational | 2 |
How many Gingival Hyperplasia trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 1 |
| Enrolling by invitation | 1 |
| Completed | 14 |
| Unknown status | 2 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which drugs are being tested for Gingival Hyperplasia? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Platelet Rich Fibrin | 1 |
| Folic (or folinic) acid | 1 |
Interventions as named in the registry (7)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Low Level Laser Therapy | 1 |
| PRF group | 1 |
| Injectable Platelet Rich Fibrin | 1 |
| Control (placebo) group | 1 |
| ozonized gel application | 1 |
Showing 5 of 7 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Gingival Hyperplasia? (12)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Efficacy of hyaluronic acid gel and photobiomodulation therapy on wound healing after surgical gingivectomy: a randomized controlled clinical trial. | BMC oral health | 2023 | Yes |
| Gingivectomy with Diode Laser Versus the Conventional Scalpel Surgery and Nonsurgical Periodontal Therapy in Treatment of Orthodontic Treatment-Induced Gingival Enlargement: A Systematic Review. | Photobiomodulation, photomedicine, and laser surgery | 2023 | Yes |
| Conversion to tacrolimus once-daily from ciclosporin in stable kidney transplant recipients: a multicenter study. | Transplant international : official journal of the European Society for Organ Transplantation | 2012 | Yes |
| Folic acid supplementation prevents phenytoin-induced gingival overgrowth in children. | Neurology | 2011 | Yes |
| Expression of growth factors in the gingival crevice fluid of patients with phenytoin-induced gingival enlargement. | Archives of oral biology | 2004 | Yes |
Showing 5 of 12 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: lead sponsors, serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.